Core Viewpoint - The company expects a significant loss in net profit for the fiscal year 2025, with estimates ranging from a loss of 228 million yuan to 153 million yuan, and a non-recurring loss between 237 million yuan and 159 million yuan, indicating a worsening financial outlook compared to the previous year's losses [1] Group 1 - The primary reasons for the anticipated losses include market fluctuations and increased industry competition, leading to extended project acquisition cycles, with the company prioritizing orders that have financial backing [1] - The company is incurring high market expansion expenses to develop new business and transform traditional operations [1] - Delays in accounts receivable collection due to clients' budget and funding allocation issues have resulted in the company recognizing credit impairment losses [1]

Core Viewpoint - Yibai Pharmaceutical announced a profit warning for the fiscal year 2025, expecting a net loss attributable to shareholders of between 285 million to 342 million yuan, indicating a significant deterioration compared to a loss of 317.22 million yuan in the same period last year [1] Financial Performance - The company anticipates a decline in revenue due to reduced sales of its main products [1] - Although costs have decreased, they remain higher than revenue, contributing to the expected losses [1] - The company plans to recognize an impairment provision for goodwill between 110 million to 132 million yuan, which will further exacerbate the losses [1]

Group 1 - The company expects a loss of 2.00 million to 4.00 million yuan in 2025, with a non-recurring loss of 15.00 million to 20.00 million yuan [1] - The primary reason for the performance change is that the newly expanded health consumer products and medical health business segments are still in the market cultivation phase, leading to high fixed cost allocation and a temporary impact on overall profits [1] - The estimated impact of non-recurring gains and losses on net profit during the reporting period is approximately 13.00 million to 16.00 million yuan [1]

Core Viewpoint - The company expects a net profit loss attributable to shareholders of 2 to 4 million yuan in 2025, compared to a profit of 4.1627 million yuan in the same period last year [1] Group 1: Financial Performance - The primary reason for the performance change is that the newly expanded health consumer products and medical health business segments are still in the market cultivation phase, leading to high fixed cost allocation and a temporary impact on overall profits [1] - The company estimates that non-recurring gains and losses will impact net profit by approximately 13 to 16 million yuan during the reporting period [1]

Group 1: New Five Feng - New Five Feng expects a net profit loss of 7 billion to 9.6 billion yuan for 2025, a significant decline from profit in the previous year [1] - The company attributes the loss to a substantial decrease in pig prices compared to the previous year and the need to account for inventory impairment on biological assets [1] - In 2025, New Five Feng's pig sales volume is projected to be approximately 5.4224 million heads, an increase of over 25% from 4.1663 million heads in 2024, with Q4 sales reaching 1.8669 million heads, a 66.4% increase from Q3 [1] Group 2: Bright Meat Industry - Bright Meat Industry anticipates a net loss of 1.16 billion to 1.71 billion yuan for 2025, marking its first loss in fifteen years [2] - The primary reason for the loss is the poor performance of the pig farming sector, driven by low domestic market prices [2] - The company is working on cost reduction and efficiency improvements in pig farming, but the significant drop in sales prices has led to substantial losses [2] Group 3: Lihua Co., Ltd. - Lihua Co., Ltd. forecasts a net profit of 550 million to 600 million yuan for 2025, representing a year-on-year decline of 60.55% to 63.84% [3] - The company's complete cost for meat chickens is approximately 11.4 yuan/kg, while the complete cost for pigs is about 12.3 yuan/kg, both of which are among the highest in the industry [3] Group 4: Yike Foods - Yike Foods projects a net profit loss of 260 million to 290 million yuan for 2025, a drastic decline from a profit of 100 million yuan in the previous year, marking the worst annual report since its listing [4] - The company's revenue is expected to decrease by about 9% due to a larger decline in sales prices compared to cost reductions, leading to a significant reduction in gross profit [5] - The duck product segment has seen a gross profit decrease of approximately 220 million yuan, while duckling gross profit has decreased by about 270 million yuan, contributing to the overall decline [5]

1月20日，赛为智能发布2025年度业绩预告，公司亏损规模较上年同期显著扩大，且期末净资产可能为 负，面临退市风险警示。 其中，归属于上市公司股东的净利润预计亏损72,000万元至102,000万元，较上年同期的亏损50,731.58万 元，同比增亏41.92%至101.06%；扣除非经常性损益后的净利润预计亏损69,000万元至98,000万元，较上年 同期的亏损21,783.44万元，亏损大幅扩大216.75%至349.88%。 财务状况方面，截至2025年末，公司归属于上市公司股东的所有者权益预计为-87,000万元至-62,000万元， 较上年末的12,243.99万元大幅下滑，净资产可能转为负值。 对于业绩大幅亏损及净资产可能为负的原因，赛为智能表示，主要受与深圳市艾特网能技术有限公司的诉 讼、仲裁判决影响，该事项对2025年度净利润的影响约为-7.18亿元。 ...

至于报废原因，一方面，公司根据目前的市场形势判断澳洲、甘肃和新疆基地每年的原酒供应足以满足 未来4—5年每年的生产销售需要；另一方面，公司因受实控人事件影响，经营现金流较为紧张，需减少 未能带来及时现金流的非必要业务支出（包含对龙湖基地的持续资金投入），以保证公司目前正常的生 产经营；公司后续将寻找租户将土地对外出租获取租金收入。 2024年12月25日，威龙股份公告披露，实控人闫鹏飞涉嫌挪用资金被监视居住。去年12月底，控股股东 星河息壤因未履行增持承诺被上交所通报批评，星河息壤理由是"持有的股票被司法冻结，且筹措资金 困难"，其实控人为闫鹏飞。截至2025年11月11日，星河息壤持有威龙股份18.84%的股份，但其中累计 被冻结和标记的股份合计占其持股比例达86.47%，占公司总股本的16.29%。 除了"砍藤"，库存原酒的处理也显露了威龙股份的困境，公司预计对原酒计提减值金额达3875万元。 2026年公司生产技术质量科对库存原酒进行了质量等级鉴定，对现存原酒进行等级划分，针对年份较 长，质量下降已无法调配葡萄酒的原酒，规划后续用来蒸馏酒精后调配白兰地使用。 公开资料显示，威龙股份成立于1982年，系集 ...

Core Viewpoint - The company Shandong Weilong Co., Ltd. is expected to report a significant loss for the fiscal year 2025, with projected net losses ranging from 40.92 million to 66.11 million yuan, primarily due to a combination of market downturns and substantial asset write-offs [1][2]. Financial Performance - The company anticipates operating revenue between 341 million and 391 million yuan for 2025, with main business revenue expected to be between 315 million and 360 million yuan [2]. - The projected net loss for 2025 marks a stark contrast to the previous year's profit of 10.26 million yuan [2]. Asset Management - The company plans to scrap 600 acres of its 1,000-acre grape planting base, retaining only 400 acres for tourism purposes, which is expected to incur a loss of approximately 11.18 million yuan [2][3]. - A significant impairment of 38.75 million yuan is expected for inventory of raw wine due to quality degradation [3]. Operational Challenges - The company is facing operational difficulties, including a tight cash flow situation influenced by the actions of its controlling shareholder, which has led to a reduction in non-essential business expenditures [3]. - Legal issues have arisen from a subsidiary's inability to cultivate high-quality wine grapes, resulting in a provision for expected losses of 28 million yuan [4]. Governance Issues - The controlling shareholder, Xinghe Xirang, has faced criticism for failing to fulfill a commitment to increase shareholding, with no shares purchased despite a prior promise [5][6]. - The controlling shareholder is also embroiled in legal troubles, including allegations of fund misappropriation, which have further complicated the company's financial stability [6]. Market Position - The company is attempting to adapt to market conditions by planning to develop entry-level wines aimed at younger consumers and markets in lower-tier cities and rural areas [3].

锦和商管公告称，预计2025年年度归属于上市公司股东的净利润为-12,500.00万元到-7,500.00万元，扣 非净利润为-22,500.00万元到-17,500.00万元；上年同期净利润为1,475.32万元，扣非净利润为-9,580.64万 元。业绩变动主因是商办市场需求承压、租金下行，主营业务毛利率下滑，且拟对部分资产及商誉计提 减值准备。不过，与同昌盛业的交易确认公允价值变动收益，对净利润有正面影响。 ...

Group 1 - The company, Liangpinpuzi, forecasts a net profit attributable to shareholders for 2025 to be between -160 million and -120 million yuan, with a net profit excluding non-recurring gains and losses expected to be between -190 million and -150 million yuan [1] - In 2024, Liangpinpuzi reported an operating revenue of 7.159 billion yuan, a year-on-year decrease of 11.02%, and a net profit attributable to shareholders of -46.10 million yuan, compared to a profit of 180 million yuan in the previous year [1] - The net cash flow from operating activities for 2024 was 577.15 million yuan, reflecting a significant decline of 99.55% year-on-year [1] Group 2 - Liangpinpuzi raised a total of 487.90 million yuan from its initial public offering, with a net amount of 420.47 million yuan, exceeding the original plan by 117,900 yuan [2] - The funds raised are intended for projects including the construction of an all-channel marketing network, warehousing and logistics system, digital upgrade of information systems, and renovation of food research and testing centers [2] - The total issuance costs for the initial public offering amounted to 67.43 million yuan, with underwriting and sponsorship fees accounting for 42.03 million yuan [3]